Market Research Logo

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia - Pipeline Revi


Introduction
Global Markets Direct Report Coverage
Heterozygous familial hypercholesterolemia (heFH) - Overview
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development
Daewoong Co Ltd
Esperion Therapeutics Inc
Gemphire Therapeutics Inc
Innovent Biologics Inc
Madrigal Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
The Medicines Company
Heterozygous familial hypercholesterolemia (heFH) - Drug Profiles
(bempedoic acid + ezetimibe) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alirocumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gemcabene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBI-306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGL-3196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGL-3745 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products
Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones
Featured News & Press Releases
Aug 27, 2018: Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study
Feb 20, 2018: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule
Feb 08, 2018: Madrigal's MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia
Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit
Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia
May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196
Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection
Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia
Jan 05, 2017: Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection
Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia
Nov 11, 2016: Regeneron and Sanofi to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016
Aug 29, 2016: Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
May 24, 2016: New Cholesterol Treatment Now Available for Canadians
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Co Ltd, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Esperion Therapeutics Inc, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Gemphire Therapeutics Inc, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Innovent Biologics Inc, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Madrigal Pharmaceuticals Inc, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Pipeline by The Medicines Company, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H2 2018
Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018
Number of Products under Development by Companies, H2 2018 8
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report